


APPLICATION

Carvedilol and Related Substances

Ph. Eur. monograph 1745



Overview

The Ph. Eur. Monograph 1745 outlines the separation of Carvedilol from impurities. This method was studied and improvements were made to provide faster separations within allowable adjustments.

Ph. Eur. Monograph 1745 Details

Reference Solution

(b) Dissolve 5 mg of Carvedilol Impurity C CRS* in 5.0 mL of the mobile phase and dilute to 100.0 mL with the mobile phase. Dilute 4.0 mL of the solution to 100.0 mL with the mobile phase. Dilute 1.0 mL of this solution to 10.0 mL with the mobile phase.

(c) Dissolve 5 mg of Carvedilol for system suitability CRS* (containing Impurities A and D) in the mobile phase and dilute to 50.0 mL with the mobile phase.

Column

Size	150 x 4.6 mm
Stationary Phase	End-capped octylsilyl silica gel for chromatography R (5 µm)
Temperature	55 °C
Mobile Phase	Dissolve 1.77 g of potassium dihydrogen phosphate R in water and dilute to 650 mL with the same solvent; adjust to pH 2.0 with phosphoric acid R and add 350 mL of acetonitrile R
Flow Rate	1.0 mL/min
Detection	Spectrophotometer @ 240 nm
Injection	20 µL
Run Time	6 times the retention time of Carvedilol

Relative Retention with Reference to Carvedilol (about 4 min)**


Impurity A	about 0.5
Impurity C	about 2.9
Impurity D	about 3.8

System Suitability

Reference Solution (b) Minimum resolution of 3.5 between peaks due to Impurity A and Carvedilol

*Carvedilol Impurity C CRS (Y0000103) and Carvedilol for system suitability CRS (Y0001426) were purchased from European Directorate for the Quality of Medicines & HealthCare (EDQM) – Council of Europe; Postal address: 7 Allée Kastner CS 30026F - 67081 STRASBOURG (France).

** Retention times, relative retentions, and retardation factors are provided for information only and are not mandatory, no deviation allowance is defined.



Adjustments for Meeting System Suitability

(European Pharmacopeia 9.0, Chapter 2.2.46. Chromatographic separation techniques)

Method Parameter	Allowed Adjustments (isocratic elution)	Method 1
Mobile Phase pH	± 0.2 units	2.0 (as specified)
Concentration of Salts in Buffer	± 10 %	As specified in Monograph 1745 Details Table
Composition of the Mobile Phase	± 30 % of the minor solvent component relative or 2 % absolute, whichever is the larger. No other component is altered by more than 10 % absolute.	As specified in Monograph 1745 Details Table
Wavelength of Detector	No deviations permitted	240 nm (as specified)
Injection Volume	May be decreased, provided detection and repeatability of the peak(s) to be determined are satisfactory.	20 µL (as specified)
Column Temperature	± 10 °C	55 °C (as specified)
Stationary Phase	No change of the identity of the substituent permitted (e.g. no replacement of C8 by C18)	Octylsilyl silica gel for chromatography (as specified)
Column Length	± 70 %	150 mm (as specified)
Column Internal Diameter	± 25 %	4.6 mm (as specified)
Particle Size	-50 %	5 µm (as specified)
Flow Rate	± 50 %	1.0 mL/min (as specified)

Kinetex® Ordering Information

5 µm Minibore Columns (mm)					SecurityGuard™ ULTRA Cartridges [†]
Phases	30 x 2.1	50 x 2.1	100 x 2.1	150 x 2.1	3/pk
C8	—	00B-4608-AN	00D-4608-AN	—	AJ0-8784 for 2.1 mm ID

5 µm MidBore™ Columns (mm)				SecurityGuard ULTRA Cartridges [†]
Phases	50 x 3.0	100 x 3.0	150 x 3.0	3/pk
C8	00B-4608-Y0	00D-4608-Y0	—	AJ0-8777 for 3.0 mm ID

5 µm Analytical Columns (mm)					SecurityGuard ULTRA Cartridges [†]
Phases	50 x 4.6	100 x 4.6	150 x 4.6	250 x 4.6	3/pk
C8	00B-4608-E0	00D-4608-E0	00F-4608-E0	00G-4608-E0	AJ0-8770 for 4.6 mm ID

[†]SecurityGuard ULTRA Cartridges require holder, Part No.: AJ0-9000



If Phenomenex products in this technical note do not provide at least an equivalent separation as compared to a competing product of the same particle size, similar phase and dimensions, return the product with comparative data within 45 days for a FULL REFUND.

APPLICATION

Australia

t: +61 (0)2-9428-6444
f: +61 (0)2-9428-6445
auinfo@phenomenex.com

Austria

t: +43 (0)1-319-1301
f: +43 (0)1-319-1300
anfrage@phenomenex.com

Belgium

t: +32 (0)2 503 4015 (French)
t: +32 (0)2 511 8666 (Dutch)
f: +31 (0)30-2383749
beinfo@phenomenex.com

Canada

t: +1 (800) 543-3681
f: +1 (310) 328-7768
info@phenomenex.com

China

t: +86 400-606-8099
f: +86 (0)22 2532-1033
phen@agela.com

Denmark

t: +45 4824 8048
f: +45 4810 6265
nordicinfo@phenomenex.com

Finland

t: +358 (0)9 4789 0063
f: +45 4810 6265
nordicinfo@phenomenex.com

France

t: +33 (0)1 30 09 21 10
f: +33 (0)1 30 09 21 11
franceinfo@phenomenex.com

Germany

t: +49 (0)6021-58830-0
f: +49 (0)6021-58830-11
anfrage@phenomenex.com

India

t: +91 (0)40-3012 2400
f: +91 (0)40-3012 2411
indiainfo@phenomenex.com

Ireland

t: +353 (0)1 247 5405
f: +44 1625-501796
eireinfo@phenomenex.com

Italy

t: +39 051 6327511
f: +39 051 6327555
italiainfo@phenomenex.com

www.phenomenex.com

Phenomenex products are available worldwide. For the distributor in your country, contact Phenomenex USA, International Department at international@phenomenex.com

Luxembourg

t: +31 (0)30-2418700
f: +31 (0)30-2383749
nlinfo@phenomenex.com

Mexico

t: 01-800-844-5226
f: 001-310-328-7768
tecnicomx@phenomenex.com

The Netherlands

t: +31 (0)30-2418700
f: +31 (0)30-2383749
nlinfo@phenomenex.com

New Zealand

t: +64 (0)9-4780951
f: +64 (0)9-4780952
nzinfo@phenomenex.com

Norway

t: +47 810 02 005
f: +45 4810 6265
nordicinfo@phenomenex.com

Puerto Rico

t: +1 (800) 541-HPLC
f: +1 (310) 328-7768
info@phenomenex.com

Spain

t: +34 91-413-8613
f: +34 91-413-2290
espinfo@phenomenex.com

Sweden

t: +46 (0)8 611 6950
f: +45 4810 6265
nordicinfo@phenomenex.com

United Kingdom

t: +44 (0)1625-501367
f: +44 (0)1625-501796
ukinfo@phenomenex.com

USA

t: +1 (310) 212-0555
f: +1 (310) 328-7768
info@phenomenex.com

All other countries Corporate Office USA

t: +1 (310) 212-0555
f: +1 (310) 328-7768
info@phenomenex.com

Terms and Conditions

Subject to Phenomenex Standard Terms and Conditions which may be viewed at www.phenomenex.com/TermsAndConditions.

Trademarks

Kinetex is a registered trademarks and MidBore and SecurityGuard are trademarks of Phenomenex.

© 2017 Phenomenex, Inc. All rights reserved.

